May 30: The Week in Cancer News
AI can help doctors determine which breast cancer patients qualify for targeted therapy, and cancer deaths among women have increased with rising temperatures in some countries.
Progress Against Cancer
AI can help doctors determine which breast cancer patients qualify for targeted therapy, and cancer deaths among women have increased with rising temperatures in some countries.
This month, the editors of AACR’s journals picked studies highlighting genetic parallels between cancer evolution and high-altitude physiology, data linking oil and gas exposure to childhood leukemia risk, and more.
The AACR Annual Meeting 2025, held April 25-30, featured six Plenary Sessions that explored exciting areas of cancer research, including cancer evolution; KRAS, extrachromosomal DNA (ecDNA), and cancer vaccines; innovative technology advancing organoid models,...
The latest edition of From the Bench features creative cancer research, including making tumors seem like pig organs, starving cancer with fat, and more.
Disasters present a threat to cancer care, and understanding prostate cancer screening recommendations after President Joe Biden’s diagnosis.
At the AACR Annual Meeting 2025, researchers and patient advocates shared insights into the impact of NIH funding cuts on cancer research.
Learn how a Gleason score is calculated to help determine the aggressiveness of prostate cancer, and how it could influence a patient's treatment.
Research unveiled at the AACR Annual Meeting 2025 highlighted advances in blood-based liquid biopsy tests to help improve cancer care.
Study examines benefit of PARP inhibitors before surgery in BRCA-related breast cancer, and exercise improves sexual function after prostate cancer treatment.
Clinical trial results reported at the AACR Annual Meeting 2025 showcased new therapeutic approaches for non-small cell lung cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More